PharmaSGP Continues Dynamic Growth Path in First Half of 2024

PharmaSGP Holding SE, the German OTC pharmaceutical company, reported impressive preliminary results for the first half of 2024, achieving revenues of €58.4 million. This reflects a 17.4% increase compared to last year's revenues of €49.7 million. Adjusted EBITDA also rose from €15.3 million to €16.9 million, though the adjusted EBITDA margin slightly decreased to 28.9% from 30.9%.

CEO Natalie Weigand emphasized the successful first half, attributing record revenues to their robust business model, scalable platform, and multi-channel marketing approach. The appointment of Peter Gerckens as Chief Commercial Officer in July 2024 aimed to bolster their international market expansion.

CFO Michael Rudolf highlighted the company's progress toward growth targets for 2024. He noted significant development in Italy, where revenues nearly doubled. For 2024, the company projects revenues between €107.0 million and €112.0 million and an adjusted EBITDA of €35.0 - €38.0 million.